This inventor holds 1 USPTO granted patent and 4 published patent applications and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Xuchun Zheng: Innovator in Metabolic Disorder Treatments
Introduction
Xuchun Zheng is a notable inventor based in Changshu, China. He has made significant contributions to the field of medicinal chemistry, particularly in the treatment of metabolic disorders. His innovative work has led to the development of a patent that addresses critical health issues.
Latest Patents
Xuchun Zheng holds a patent for "Cyclic bridgehead ether DGAT1 inhibitors." This invention relates to compounds that are useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1). These disorders include various metabolic conditions. The patent also outlines methods for treating such disorders, along with compounds and compositions designed for their treatment.
Career Highlights
Zheng is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions for complex health challenges. His expertise in medicinal chemistry has been instrumental in advancing therapeutic options for patients.
Collaborations
Xuchun Zheng collaborates with talented professionals in his field, including Sejal Patel and Justin Mao. These partnerships enhance the research and development process, fostering an environment of innovation and creativity.
Conclusion
Xuchun Zheng's contributions to the field of metabolic disorder treatments exemplify the impact of innovative thinking in healthcare. His patent for DGAT1 inhibitors represents a significant advancement in therapeutic options for patients suffering from metabolic disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile